Real-world evidence (RWE) is key to accelerating oncology approvals

RWE has emerged as a valuable complementary resource to provide information beyond what is learned from randomized clinical trials Advances in technology and analytics are enabling real-world data to be gathered in real time and analyzed to help make clinical, payer, policy, and regulatory decisions The capability of RWE to create a more robust view…

Read More

Treating cancer with messenger RNA (mRNA) vaccines

mRNA vaccines have emerged more recently and have been headlined with the Pfizer-BioNTech and Moderna vaccines for COVID-19. Knowing exactly which mutations an individual’s cancer carries could allow scientists to develop mRNA vaccines specific to their particular cancer. Customising treatment in this way, whether for cancer or other diseases, is known as personalised medicine. “The…

Read More

Rheumatology real-world evidence studies are clinically important, but require careful interpretation

Real-world evidence studies such as a recent study by Fisher (1) examining the persistence of JAK1/3 inhibitor tofacitinib in patients with RA compared to the persistence of bDMARD of a large, retrospective new user cohort from in a research database, are informative but require cautious interpretation because findings are dependent on a variety of medical…

Read More

Roche, BC Cancer & CPHIN collaborate to generate real-world evidence

This collaboration, called Precision Oncology Evidence Development in Cancer Treatment, or PREDiCT, aims to generate and assess real-world evidence, and with this data influence the development of new reimbursement pathways for precision oncology therapies Biomarker-informed precision oncology drugs are often indicated for rare subpopulations of cancer patients, making traditional analyses difficult – PREDiCT will encourage…

Read More